Shitara, K., Di Bartolomeo, M., Mandala, M., Ryu, M., Caglevic, C., Olesinski, T., . . . Özgüroğlu, M. (2023). Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: Exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. Journal for ImmunoTherapy of Cancer, 11(6), e006920. https://doi.org/10.1136/jitc-2023-006920
Citácia podle Chicago (17th ed.)Shitara, Kohei, et al. "Association Between Gene Expression Signatures and Clinical Outcomes of Pembrolizumab Versus Paclitaxel in Advanced Gastric Cancer: Exploratory Analysis from the Randomized, Controlled, Phase III KEYNOTE-061 Trial." Journal for ImmunoTherapy of Cancer 11, no. 6 (2023): e006920. https://doi.org/10.1136/jitc-2023-006920.
Citácia podľa MLA (8th ed.)Shitara, Kohei, et al. "Association Between Gene Expression Signatures and Clinical Outcomes of Pembrolizumab Versus Paclitaxel in Advanced Gastric Cancer: Exploratory Analysis from the Randomized, Controlled, Phase III KEYNOTE-061 Trial." Journal for ImmunoTherapy of Cancer, vol. 11, no. 6, 2023, p. e006920, https://doi.org/10.1136/jitc-2023-006920.